Wall Street brokerages forecast that Alkermes PLC (NASDAQ:ALKS) will report earnings per share (EPS) of $0.01 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Alkermes PLC’s earnings, with the lowest EPS estimate coming in at ($0.02) and the highest estimate coming in at $0.05. Alkermes PLC reported earnings of ($0.09) per share during the same quarter last year, which would suggest a positive year over year growth rate of 111.1%. The firm is scheduled to issue its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Alkermes PLC will report full year earnings of ($0.04) per share for the current financial year, with EPS estimates ranging from ($0.09) to $0.04. For the next financial year, analysts expect that the business will report earnings of $0.38 per share, with EPS estimates ranging from $0.22 to $0.67. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Alkermes PLC.

Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company had revenue of $218.80 million for the quarter, compared to the consensus estimate of $216.54 million. During the same quarter in the previous year, the business earned ($0.01) earnings per share. The company’s revenue for the quarter was up 12.1% on a year-over-year basis.

A number of brokerages have weighed in on ALKS. ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. BidaskClub lowered Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Alkermes PLC currently has a consensus rating of “Hold” and a consensus target price of $62.89.

In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total value of $82,365.00. Following the transaction, the director now directly owns 9,500 shares of the company’s stock, valued at $521,645. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the transaction, the chief accounting officer now directly owns 70,455 shares in the company, valued at $3,613,636.95. The disclosure for this sale can be found here. Insiders sold 18,066 shares of company stock worth $941,485 over the last three months. 5.34% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in ALKS. BlackRock Inc. raised its position in Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock valued at $602,115,000 after purchasing an additional 10,121,839 shares during the period. Janus Henderson Group PLC raised its position in Alkermes PLC by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock valued at $135,128,000 after purchasing an additional 2,314,203 shares during the period. Primecap Management Co. CA raised its position in Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock valued at $459,608,000 after purchasing an additional 1,480,273 shares during the period. Janus Capital Management LLC raised its position in Alkermes PLC by 220.0% in the first quarter. Janus Capital Management LLC now owns 1,658,928 shares of the company’s stock valued at $97,045,000 after purchasing an additional 1,140,555 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Alkermes PLC by 40.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,857,077 shares of the company’s stock valued at $167,138,000 after purchasing an additional 820,355 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Alkermes PLC (NASDAQ ALKS) traded up 0.06% during midday trading on Thursday, reaching $52.32. The company’s stock had a trading volume of 611,048 shares. Alkermes PLC has a 1-year low of $41.93 and a 1-year high of $63.40. The firm’s market cap is $8.04 billion. The company has a 50 day moving average price of $52.09 and a 200 day moving average price of $56.69.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/14/alkermes-plc-alks-expected-to-announce-earnings-of-0-01-per-share.html.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Get a free copy of the Zacks research report on Alkermes PLC (ALKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.